Abstract
Increased recognition of the limits of conventional medicine has helped drive the growing interest in complementary and alternative medicine which is now being commonly used in patients with chronic diseases, including individuals with Crohn’s disease and ulcerative colitis. Recently, scientific interest has unraveled the beneficial pharmacological effects of curcumin. We present an updated concise review of currently available in vitro, animal and clinical studies demonstrating the therapeutic effect of herbal medication in inflammatory bowel disease.
Journal Section:
Review
References
1.
Hanauer SB: Inflammatory bowel disease. N Engl J Med 1996;334:841–848.
[PubMed]
2.
Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002;347:417–429.
[PubMed]
3.
Rutgeerts P, Van Assche G, Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593–1610.
[PubMed]
4.
Galloway JB, et al: Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124–131.
5.
Afif W, Loftus EV Jr: Safety profile of IBD therapeutics: infectious risks. Med Clin North Am 2010;94:115–133.
6.
Beaugerie L, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374:1617–1625.
[PubMed]
7.
Barnes PM, Bloom B, Nahin R: CDC National Health Statistics Report No. 12. Complementary and alternative medicine use among adults and children: United States 2007. Hyattsville, National Center for Health Statistics, 2008.
8.
Hilsden RJ, et al: Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:655–662.
9.
Ruby AJ, et al: Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995;94:79–83.
10.
Ramsewak RS, DeWitt DL, Nair MG: Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I–III from Curcuma longa. Phytomedicine 2000;7:303–308.
11.
Aggarwal BB, Harikumar KB: Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009;41:40–59.
12.
Rao DS, et al: Effect of curcumin on serum and liver cholesterol levels in the rat. J Nutr 1970;100:1307–1315.
13.
Negi PS, et al: Antibacterial activity of turmeric oil: a byproduct from curcumin manufacture. J Agric Food Chem 1999;47:4297–4300.
14.
Yadav VR, et al: Effect of cyclodextrin complexation of curcumin on its solubility and antiangiogenic and anti-inflammatory activity in rat colitis model. AAPS Pharm Sci Tech 2009;10:752–762.
15.
Subramanian L, Selvam R: Prevention of CCI4-induced hepatotoxicity by aqueous extract of turmeric. Nutr Res 1999;19:429–441.
16.
Wilczynski NL, Haynes RB: Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Med 2004;2:23.
[PubMed]
17.
Haynes RB, et al: Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc 1994;1:447–458.
18.
Haynes RB, Kastner M, Wilczynski NL: Developing optimal search strategies for detecting clinically sound and relevant causation studies in EMBASE. BMC Med Inform Decis Making 2005;5:8.
19.
Billerey-Larmonier C, et al: Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis 2008;14:780–793.
20.
Camacho-Barquero L, et al: Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 2007;7:333–342.
[PubMed]
21.
Deguchi Y, et al: Curcumin prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis. Dig Dis Sci 2007;52:2993–2998.
22.
Jiang H, et al: Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 2006;12:3848–3853.
23.
Larmonier CB, et al: Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. Inflamm Bowel Dis 2011;17:503–515.
24.
Larmonier CB, et al: Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. Am J Physiol Gastrointest Liver Physiol 2008;295:G1079–G1091.
25.
Lubbad A, Oriowo MA, Khan I: Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 2009;322:127–135.
[PubMed]
26.
Nones K, et al: The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a–/–) mice, a model of inflammatory bowel diseases. Br J Nutr 2009;101:169–181.
[PubMed]
27.
Salh B, et al: Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 2003;285:G235–G243.
[PubMed]
28.
Sugimoto K, et al: Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002;123:1912–1922.
29.
Ukil A, et al: Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003;139:209–218.
30.
Venkataranganna MV, et al: NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol 2007;13:1103–1107.
[PubMed]
31.
Zhang M, et al: Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 2006;27:1071–1077.
32.
Cuendet M, Pezzuto JM: The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact 2000;17:109–157.
33.
Han SS, et al: Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 1999;93:152–161.
[PubMed]
34.
Boone DL, Ma A: Connecting the dots from Toll-like receptors to innate immune cells and inflammatory bowel disease. J Clin Invest 2003;111:1284–1286.
35.
Ranjan D, et al: Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkappaB activation, and IL-2 signaling. J Surg Res 2004;121:171–177.
36.
Ranjan D, et al: Curcumin blocks cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation. J Surg Res 1998;77:174–178.
37.
Jagetia GC, Aggarwal BB: ‘Spicing up’ of the immune system by curcumin. J Clin Immunol 2007;27:19–35.
38.
Bhaumik S, Jyothi MD, Khar A: Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett 2000;483:78–82.
39.
Xinjian L, Xiaocheng L: Effect of curcumin on immune function of mice. J Huazhong Univ Sci Technol Med Sci 2005;25:137–140.
40.
Joe B, Lokesh BR: Role of capsaicin, curcumin and dietary n–3 fatty acids in lowering the generation of reactive oxygen species in rat peritoneal macrophages. Biochim Biophys Acta Mol Cell Res 1994;1224:255–263.
[PubMed]
41.
Joe B, Lokesh B: Dietary n–3 fatty acids, curcumin and capsaicin lower the release of lysosomal enzymes and eicosanoids in rat peritoneal macrophages. Mol Cell Biochem 2000;203:153–161.
42.
Marks DJ, Segal AW: Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol 2008;214:260–266.
[PubMed]
43.
Midura-Kiela MT, et al: Curcumin inhibits interferon-gamma signaling in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2012;302:G85–G96.
44.
Hanai H, Sugimoto K: Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 2009;15:2087–2094.
45.
Hsu CH, Cheng AL: Clinical studies with curcumin. Adv Exp Med Biol 2007;595:471–480.
46.
Cheng AL, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895–2900.
[PubMed]
47.
Sharma RA, et al: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001;7:1894–1900.
48.
Sharma RA, et al: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847–6854.
49.
Rao CV: Regulation of COX and LOX by curcumin. Adv Exp Med Biol 2007;595:13–26.
50.
Prakobwong S, et al: Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int J Cancer 2011;129:88–100.
51.
Menon VP, Sudheer AR: Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007;595:105–125.
[PubMed]
52.
Holt PR, Katz S, Kirshoff R: Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005;50:2191–2193.
53.
Hanai H, et al: Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:1502–1506.
54.
Pan MH, Huang TM, Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 1999;27:486–494.
55.
Holder GM, Plummer JL, Ryan AJ: The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 1978;8:761–768.
56.
Jian YT, et al: Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 2005;11:1747–1752.
57.
Martelli L, et al: A potential role for the vanilloid receptor TRPV1 in the therapeutic effect of curcumin in dinitrobenzene sulphonic acid-induced colitis in mice. Neurogastroenterol Motil 2007;19:668–674.
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
